Tarsus Pharmaceuticals (TARS) Change in Acquisitions & Divestments (2022 - 2026)

Tarsus Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $74.1 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 18.82% year-over-year to $74.1 million; the TTM figure through Mar 2026 stood at $344.6 million (up 113.11% YoY), while the FY2025 annual figure was $361.8 million, up 395.62% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $74.1 million, down from $92.1 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $99.5 million in Q3 2025, with the low at $2.5 million in Q1 2024.
• The 5-year median for Change in Acquisitions & Divestments is $46.0 million (2023), against an average of $49.2 million.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments slumped 93.8% in 2024, then surged 3548.72% in 2025.
• Tarsus Pharmaceuticals' Change in Acquisitions & Divestments stood at $5.3 million in 2022, then surged by 235.84% to $17.8 million in 2023, then jumped by 98.68% to $35.5 million in 2024, then jumped by 159.64% to $92.1 million in 2025, then slipped by 19.58% to $74.1 million in 2026.
• Business Quant data shows TARS's Change in Acquisitions & Divestments at $74.1 million in Q1 2026, $92.1 million in Q4 2025, and $99.5 million in Q3 2025.